Previous 10 | Next 10 |
22nd Century Group, Inc. (XXII) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Mei Kuo - Director of Communications and Investor Relations Michael Zercher - President and Chief Operating Officer Andrea Jentsch - Chief Financial Officer Conference ...
22nd Century (NYSEMKT: XXII ): Q1 GAAP EPS of -$0.03. More news on: 22nd Century Group, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, today reported results for the first quarter ended...
Research Validates New Non-GMO Methodologies for Reducing Nicotine in Tobacco Plants by up to 99% 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and ...
Williamsville, NY, April 28, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and develop...
The FDA has set Monday, May 18, as the end date for the public to submit comments concerning 22nd Century Group's ( XXII +8.2% ) Modified Risk Tobacco Product Application seeking approval of its reduced nicotine cigarettes, branded as VLN. More news on: 22nd Century Group, Inc., Health...
WILLIAMSVILLE, NY, April 17, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine content tobacco and hemp/cannabis plant genetics research and...
Williamsville, NY, April 08, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and develop...
Maintains Strong Balance Sheet; Momentum Continues for Modified Risk Tobacco Product and Major Milestone Achieved in Hemp/Cannabis Research 22nd Century Group, Inc. (NYSE American: XXII), a leading plant biotechnology company in reduced nicotine tobacco and hemp/cannabis plant gene...
Delivers Complete High-Quality Hemp/Cannabis Genome Sequence; Establishes New Proprietary Hemp/Cannabis Bioinformatics Platform WILLIAMSVILLE, N.Y. , March 11, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant biotechnology company in reduced ...
News, Short Squeeze, Breakout and More Instantly...
22nd Century Group Inc Company Name:
XXII Stock Symbol:
NYSE Market:
22nd Century Group Inc Website:
Patented, Fully Water Dispersing, Biodegradable Solution for World's Most Littered Item Mocksville, North Carolina--(Newsfile Corp. - July 10, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announce...
Mocksville, North Carolina--(Newsfile Corp. - July 9, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced a new agreement for full-scale commercial rollout of its VLN® reduced nicotine cont...
Mocksville, North Carolina--(Newsfile Corp. - June 25, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced a $1.5 million reduction in its secured debt via a paydown of the GVB secured promissor...